Interleukin 10 (I1.10) is a pleiotropic factor that enhances proliferation of activated human B lymphocytes and induces them to secrete high amounts of immunoglobulins. Here we show that several human B cell lines were able to constitutively secrete human (h)Ibl0. Whereas none of the pre-B nor the plasmocytic cell lines tested produced hi1-10, 25 of the 36 tested mature B cell lines (lymphoblastoid and Burkitt lymphoma cell lines) secreted hi1.10. Moreover, 24 of these 25 hI1-10-producing B cell lines contained the Epstein-Barr virus (EBV) genome, suggesting a relationship between hi1.10 production by human B cell lines and EBV expression. Accordingly, whereas polyclonal activation via triggering of surface immunoglobulins or CD40 antigen induced highly purified normal human B lymphocytes to produce only low (0.3-0.4 ng/ml) but significant amounts of hIbl0, EBV infection induced them to secrete high amounts of hi1.10 (4-9 ng/ml). Furthermore, addition of exogenous hIbl0, simultaneously to EBV infection, potentiated cell proliferation, whereas a blocking anti-Ibl0 antiserum inhibited it. Thus, hi1.10 produced by infected human B lymphocytes appears to be involved in the mechanisms of EBV-induced B cell proliferation.
T o produce specific antibodies in response to antigenic stimulations (1) , B lymphocytes interact with other immunocompetent cells. B cells are able to efficiently present antigen to T cells in an MHC-restricted context (2) , and also to produce soluble immunomodulatory mediators. Indeed, both normal and malignant B lymphocytes have the ability to secrete cytokines. The constitutive or induced secretion of I1.1 (3), I1.6 (4), TNF (5, 6) and soluble CD23 (7) has already been reported. B lymphomas, myelomas, and EBVinfected B cell lines have been described to produce I1.1 (8) , I1.5 (9), I1.6 (10), or TNF-oe and -~ (5, 6) , with some of these cytokines suspected to act as autocrine growth factors (11) (12) (13) .
I1-10 has been initially identified: (a) as a cytokine synthesis inhibitory factor, produced by Th2 cell clones, inhibiting macrophage-APC-dependent cytokine synthesis by Thl cell clones (14) ; and (b) as a Lyl + B cell lymphoma product potentiating IL-2-or I1-4-dependent proliferation of thymocytes (15, 16) . Human I1.10 (hlL-10) 1 and murine I1.10 (mI1.10) genes display >80% of homology (17, 18) . Furthermore, hi1.10 exhibits a strong DNA and amino acid sequence homology to an open reading frame of the EBV genome: BCRF1 or viral I1.10 (vii.10) (18) . vii.10 is expressed during the late stage of the virus cycle and exhibits most of the activities of h and mlbl0 (17) (18) (19) (20) . In the murine system, Ib 10, just like I1.4, enhances MHC class II expression on resting B lymphocytes and sustains B cell viability in culture (21) . In humans, II.-10 potentiates DNA replication orb cells stimulated via crosslinking of surface CD40 antigen or via surface Ig molecules (19) . Moreover, 11-10 is a very potent differentiation factor and induces B cells to secrete high amounts of IgM, G, and A (19, 20) .
The production of II-10 by normal routine B cells has already been characterized at the mRNA level by PCR and at the protein level by ELISA (22) . Moreover, as II:10 is an efficient proliferation and differentiation factor for human B cells, the present study was initiated to determine whether human B lymphocytes were able to secrete this cytokine after polyclonal activation.
Materials and Methods
Reagents. Lymphoid B cell lines were cultured in KPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 10% heat-inactivated FCS (MultiSer, Castel Hill, New South Wales, Australia), 2 mM glutamin (Gibco Laboratories), and 80/zg/ml ofgentamycin (gentalline; Schering-Plough, Levallois-Perret, France). Cultures of normal B lymphocytes were carded out in modified Iscove's medium as detailed previously (23) . Anti-Ibl0 rat mAbs 12G8, 6Bll, and 9D7 were kindly provided by Dr. J. Abrams (DNAX, Palo Alto, CA) (24) and used as purified products. The neutralizing rabbit polyclonal anti-Ibl0 antibody was raised in the laboratory. Briefly, five subcutaneous and intramuscular injections of CHOderived highly purified hlir (100/~g to I mg of the soluble protein), in combination with CFA for the first injection and then IFA, were performed, every month, on female "Fauve de Bourgogne" rabbits. I wk after the fifth injection, blood was collected, and the antisera were isolated. The antisera were used at a 1:100 dilution (see below). The corresponding control was the preimmune serum of the same rabbits before hlL-10 was injected. The murine anti-CD40 mAb 89 (25) and anti-IFN-3, mAbs A35 and B27 (26) Purified rib2 (5 x 104 U/mg) was from Amgen Biologicals (Thousand Oaks, CA). The purified rib4 (107 U/rag; batch 8ILE1002) and hIbl0 (10 6 U/mg; batch 27785-82) were obtained, respectively, as Escherichia coli and CHO cell products from ScheringPlough Research Institute (Bloomfield, NJ). For the early experiments, the hIbl0 was produced in the laboratory using a baculovirus/insect cell system with" a recombinant Autographa californica nuclear polyhedrosis virus genome containing the hill0 cDNA, kindly provided by Dr. K. W. Moore (DNAX). hIbl0 was used as Spodoptera frugipercla Sf9 cell supernatants after its infection by recombinant baculovirus. The yield was from 2 to 5 mg hIbl0 per liter of culture and was exactly calibrated against the purified rhIL-10. The vlL-10 used as standard in the vlbl0 ELISA was produced in the laboratory by Cos7 cells transfection with the vlL-10 cDNA-pF115 vector construct, also provided by Dr. K. W. Moore (DNAX). The Cos7 vIL-10 was calibrated against purified E. coliderived recombinant vlbl0 (5 x 10 s U/rag) provided by Dr. Ik. Kastdein (DNAX). In both cases, the mock control was performed using the empty vector.
Cell Lines. The CDw32/Fc3,RII-transfected Ltk-cell line (CDw32 L calls) was described earlier (27) . The Burkitt lymphoma BL, IARC 318, and IARC 518 cell lines were obtained from Dr. G. Lenoir (International Agency of Research on Cancer, Lyon, France). The majority of the lymphoblastoid cell lines has been obtained in our laboratory. The pre-B cell line pre-Alp was generated in the laboratory by Dr. D. Pandrau (manuscript in preparation). The chronic lymphocytic leukemia B cells were obtained from pathological samples, as described elsewhere (28) . The other cell lines were from American Type Culture Collection (Rockville, MD).
Cell Preparations and Cell
Cultures. B cells were isolated from tonsils, peripheral blood, spleen, and cord blood as previously described (29) . The isolated population expressed >98% CD19 or CD20 (B cells), <1% CD2 (T cells), and <1% CD14 (monocytes). Isolation of slgD § and slgD-B cell populations was performed using a magnetic activated cell sorter as previously described (20) . CD5 + B lymphocytes were isolated by cell sorting on a FACStar Plus | (Becton Dickinson & Co.). When stimulated with SAC (0.05%), anti-/~ (10/~g/ml), or PMA (1 ng/ml) + ionomycine (5 /~g/ml), B cells were cultured at 1@ cells/ml in 96-well flatbottomed microtiter plates (Falcon Labware, Oxnard, CA). In the CD40 system (30, 31) , purified B lymphocytes were cultured at 0.2-1 x 106 cells/ml with irradiated (7,500 rad) CDw32 L cells at 0.25-1 • 10 s cells/ml and with 0.5/zg/ml of anti-CD40 mAb 89. 11,4 (100 U/ml), IL-2 (20 U/ml), and IL-10 (100 ng/ml) were added when appropriate. For EBV infection of purified B lymphocytes, 50/~1 ofa 100x concentrated culture supernatant of the B95.8 viral strain was added on B cells at 10Vml in RPMI. After 2 h of incubation at 37~ cells were washed and cultured at 5 x 10 s cells/ml. For each condition, cultures were performed in triplicates. Supernatants of these cultures were harvested at different time points and tested in the II.-10 ELISAs.
Cytokine Synthesis Inhibitory Factor (CSIF) Assay. The rabbit polyclonal anti-Ibl0 antisera were tested for their ability to neutralize the activity of purified hlL.10 in CSIF assays, performed as previously described (14) . Briefly, spleen mononuclear cells were activated in 96-well flat-bottomed microtiter plates (Falcon Labware), by a combination of SAC (0.05%), PHA (5/zg/ml), and Ib2 (100 U/ml) in the presence of serial concentrations of purified hlL-10 (0.1-100 ng/ml), with or without addition of anti-IL-10 or control antisera (diluted at 1:100, 1:1,000 or 1:10,000). The neutralizing effect of the anti-IL-10 antiserum on the inhibition of IFN-3, production induced by hlL-10 was determined after 72 h of culture using an IFN-3' ELISA as previously described (26) .
11_,I0 ELISAs. Both II.-10 ELISAs are developed on the pattern of a two-site sandwich ELISA format as previously described (26) . One assay quantitates both h and vlbl0 while the other one is specific of vlbl0. Both assays rely on the same catcher mAb, 9D7, and the specificity is determined by the tracer biotinylated antibody: mAb 12G8 for the h + vlL-10 ELISA, and mAb 6Bll for the vlL-10 ELISA. Technically, the rat anti-II.,10 mAb, 9D7, was coated at 5/~g/ml for 2 h at 37~ under 100/~1, in 96-well flat-bottomed microtiter plates (Nunc Immunoplate, Roskilde, Denmark). After 3 h of saturation with BSA, superuatants were incubated 2 h at room temperature. The standards consisted of CHOderived purified hlL-10, with the concentration determined by amino acid analysis and Cos7-derived vlL-10, calibrated against purified rvlbl0. The tracer biotinylated mAbs were then incubated 2 h at room temperature: mAb 12G8 (v/hlL-10) was added at 0.05/~g/ml, and mAb 6Bll (vlL-10) was added at 0.1/xg/ml. The binding of the biotinylated antibodies was revealed with the alkaline phosphatase-conjugated streptavidin (Tago Inc., Burlingame, CA)/phosphatase substrate (Sigma Chemical Co., St. Louis, MO) system as previously described (26) . The omission or the substitution with a nonrelated biotinylated mAb of any one of the mAbs completely switched off the signal. Furthermore, 10/~g/ml of hlIr did not react in the vlL-10 ELISA and the vlL-10 similarly reacted in both IL-10 ELISAs. The lower detection levels were 100 and 50 pg/ml for the h/vlL-10 and the vlL-10, respectively. The cell line supernatants were harvested after 48-96 h of culture and then tested in the IL-10 ELISAs. For each B cell line, IL-10 concentrations are expressed as mean _+ SD of two to five independent assays. secrete hlL-10. 23 lymphoblastoid B cell lines, established from peripheral blood of normal donors, were then screened. 20 of them secreted 0.3-11 ng/ml of hlL-10. Therefore, mature human B cell lines were able to produce hiD10, and this secretion appeared to be at least partially correlated with EBV expression since 24 of the 26 hilt 10-secreting cells were EBV positive. Besides, it should be stressed that only low levels of vlL-10 could be detected in the supernatants of a restricted number of EBV-infected cell lines.
Results

Human B Cell Lines
The kinetic of hlL-10 secretion by a human B cell line was then investigated using the EBV-positive Burkitt lymphoma cell line Jijoye. B cells were initially seeded at 5 x 104 cells/ml, and the viable cell recovery was determined daily over a 96-h kinetic. The corresponding supernatants were harvested and assayed in the I1.,10 ELISAs. As illustrated in Fig. 1 , the hiD10 levels detected in the supernatants increased together with cell concentration: from 0.2 ng/ml for 10 s cells/ml after 24 h of culture, to 8.1 ng/ml for 1.4 x 106 cells/ml after 96 h of culture. The hlL-10 levels did not change even when cultures were left unsplit for several more days, resulting in a strong cell death. Thus, the highest hlir concentrations were found in the highest density Jijoye cell cultures.
Normal Human B Lymphocytes Secrete Low Levels of hlLlO upon Polyclonal Activation. To determine whether normal human B cells could also produce IL-10, highly purified B cells and total mononuclear cells, as control, were stimulated either with polyclonal activators such as PMA plus ionomycine, SAC, or anti-IgM, or in the CD40 system. Addition of IL-2 or II~4 and combinations of two different activation Mononuclear cells or purified B cells were cultured at 106 or 2 x 106 cells/ml. SAC was used at 0.05%, anti-# at 10 #g/ml, PMA at 1 ng/ml, ionomycine at 5 #g/ml, PHA at 5 #g/ml, IL-4 at 100 U/ml, and IL-2 at 20 U/ml. For the CD40 system reported as CD40, mAb 89 was used at 0.5 #g/ml, and CDw32-transfected L cells at 0. Table  2 were pooled from several independent experiments performed with tonsillar purified B lymphocytes cultured under the same conditions. Nonactivated B cells did not produce II, 10 . Upon activation, purified B cells secreted low (compared with activated total mononuclear cells) but significant and reproducible levels of hlL-10, but no v l b l 0 . For each activation mode, the hi1,10 concentration increased up to 0.3-0.4 ng/ml after 24-72 h and then progressively decreased down to the detection limit level during the next 2-3 d (see a typical kinetic in Fig. 2 ). As shown in Table 2 , doubling the number of B cells at culture onset resulted in the secretion of twice as much hi1,10. The activation of total tonsiUar mononuclear cells in the CD40 system, with or without II.,4, did not lead to higher hll~10 concentrations (data not shown), suggesting that, upon these B-specific activation procedures, the weak percentage of contaminant non-B cells could not be responsible for the hlbl0 levels observed in Table 2 . Similar levels and kinetics of hlL-10 production were also obtained with human B cells isolated from spleen and peripheral blood (data not shown).
We then investigated whether hlbl0 production was restricted to a subpopulation of normal human B cells. First, supernatants of activated IgD + and IgD-B lymphocytes contained levels of hlL-10 comparable to those of the unseparated population (data not shown). Second, CD5 + human B cells purified from cord blood were tested for their ability to secrete hlbl0 either spontaneously or after activation under conditions resulting in the production of high Ig levels, such as SAC plus IL-2 or the combination of SAC with the CD40 system (20) . As shown in Fig. 2, CD5 + B lymphocytes did not constitutively secrete hlL-10. Stimulated CD5 + B cells were able to produce low levels of hlL-10. The secretion was observed after 12 h and the peak was reached after 48 h of culture. Otherwise, resting or activated chronic lymphocytic leukemia CD5 + B cells from five different patients tested did not secrete IL-10 (data not shown). Thus, in contrast to the results generated in the murine system (22, 32) , the CD5 + B lymphocytes subpopulation did not appear to constitute the main source of hilt0 production within the whole human B cell population.
Taken together, these results indicate that activated normal human B lymphocytes are able to secrete significant levels of hlL-10, but did not reach those obtained for human B cell lines.
Normal Human B Lymphocytes Secrete High Amounts of hll_,lO after EBV Infection. Since most of the EBV-positive B cell
lines have the ability to produce hl'blO, we wondered whether EBV infection of normal B lymphocytes would induce them to secrete II.-10 levels higher than those observed in response to the polyclonal activators. Thus, tonsillar purified B cells were infected by EBV and cultured for 30 d. At different time points, culture supernatants were harvested and tested in the IL-10 ELISAs and viable cell recovery was determined using trypan blue dye exclusion. For the experiment illustrated in Fig. 3 , medium changes, indicated by arrows, were performed when B cell concentration reached saturation at "~,3 x 106 ceUs/ml. During the first 6 d after EBV infection, when strong cell death occurred, no significant amount of Ibl0 could be detected in culture supernatants. However, an induction of hlbl0 production was observed in supernatants 6 d after the culture onset, when the number of initially seeded cells was recovered. Thereafter, hlL-10 concentrations increased up to 9 ng/ml at day 14, when all the B lymphocytes acquired the typical morphology of immortalized lymphoblastoid cells and expressed Epstein-Barr nuclear antigens as detected by immunofluorescence (data not shown). At later time points, cells continued to grow with a high proliferation rate, while the hlL-10 level slowly decreased down to ml ng/ml, where it remained stable for >6 wk (data not shown). The EBV infection of purified tonsillar B cells isolated from 12 different donors led to the same results with on average 6.6 + 1.8 ng/ml of hlL-10 detected at the peak, obtained between days 14 and 19. Interestingly, no vlL-10 could be detected at any time of the kinetics. Thus, EBV transformation induces purified B lymphocytes to secrete high amounts of hlIA0. on cell growth was tested. Purified rhlL-10 was added at day 0, immediately after purified B lymphocytes had been incubated 2 h with EBV. The number of viable B cells was determined at different time points over a 20-d kinetic. Results shown in Fig. 4 are expressed as cumulative theoretical cell numbers. The addition of exogenous hlL-10 accelerated the recovery of the viable cell number initially seeded (day 4 with exogenous hll.-10 vs. day 6 for the control medium). This enhancement of cell proliferation was quite potent between days 7 and 16, when addition of exogenous hlL-10 induced a twofold increase of viable B cells. Thereafter, the effect of exogenous hll~10 became less pronounced. This potentiating effect of exogenous hlL-10 was observed on five independent experiments performed with purified B cells isolated from different donors. These results suggested that hlL-10 was a proliferation factor for EBV-infected B cells. Therefore, the endogenous secretion of hlL-10 observed during EBV infection of purified B lyrnphocytes could be involved in the mechanisms sustaining cell proliferation and leading to the establishment of the cell line.
Addition of Exogenous IL.IO Potentiates EBV-induced B Cell
Anti-IL IO-neutralizing Antiserum Inhibits EBV-induced B Cell Proliferation.
To further study the role of endogenously produced hIL-10 in the proliferation of EBV-infected B cells, we generated neutralizing polyclonal anti-IL,10 antibodies. Rabbits were immunized with highly purified rhIL-10 as described in Materials and Methods. The antisera obtained after five injections were tested for their ability to antagonize the blocking effect of purified rhIL-10 on the IFN-3' production by activated spleen mononuclear cells. As shown in Fig. 5 , the anti-IL-10 antiserum, diluted at 1:100, completely blocked the effect of 10 ng/ml of hIL-10 and antagonized 80% of the effect of 100 ng/ml, while the preimmune control serum remained inactive.
So as to block endogenous hIbl0, the neutralizing or con- trol antisera, diluted at 1:100, were added at the onset of the culture, immediately after EBV infection of B cells and thereafter every 5 d. The viable cell recovery was determined for each culture condition at different time points of the kinetic. Fig. 6 illustrates the results obtained for one of three independent experiments leading to the same following observations. The addition of anti-Ibl0 antiserum delayed the recovery of the initial cell number and strongly reduced the cell proliferation over the 22-d culture. At day 17, the number of viable cells cultured with anti-II.-10 antiserum was fivefold lower than that of cells cultured with control antiserum or in medium alone. During the same period, the control serum remained inactive. Experiments, where increasing dilutions (1:100, 1:500, 1:1,000, 1:5,000) of the anti-II.-10 and control antisera were added to infected B cells, were also performed. As illustrated in Fig. 7 A, the inhibition of cell growth was dose dependent and already observed with a dilution of 1:1,000 of the anti-II.-10 antiserum. Whatever the dilutions, the control antiserum remained inactive. Moreover, Fig. 7 A also illustrates that addition of 250 ng/ml of exogenous hlI.-10 to the 1:100 dilution of the neutralizing antiserum completely reversed its inhibitory effect and even resulted in the potentiation of B cell growth described above.
To determine when the anti-IL-10 antiserum preferentially inhibited cell growth during the 22-d kinetic shown in Fig.  6 , proliferation rates, obtained without or with anti-IL-10 or control antisera, were calculated for two intervals: between days 0 and 17, and between days 17 and 22. As illustrated in Fig. 7 B, the inhibition of the proliferation rate mediated by the neutralizing anti-II.-10 antiserum reached 80% during the first time interval, whereas the proliferation rates were identical after 17 d. Moreover, when studied after 10 wk, the cell lines established either with medium alone, control antiserum, or anti-IL-10 antiserum grew with approximately the same proliferation rate (data not shown). This indicates that the anti-IL-10 antiserum delays but does not prevent the establishment of EBV-transformed B cell lines.
Discussion
The screening of >40 B cell lines suggests that the secretion of II.-10 is associated with the mature and preplasmocytic stages of B cell development, since none of the pro-B, pre-B, or myeloma cell lines tested were able to produce IL-10. The data also indicate an association between the presence of the EBV genome and the secretion of hlir since 24 of 31 EBV-positive mature B cell lines secrete ID10, whereas only one of five EBV-negative mature B cell lines did so. It now remains to establish whether viral proteins such as EBNA 2-6 or latent membrane protein may be involved in the transactivation of the hlL-10 gene, as it has already been shown for several B cell activation markers such as CD23 or Bac-1 (33) . Nonetheless, a few EBV-positive B cell lines do not pro-duce hlL-10, and two EBV-negative B cell lines were able to secrete hlL-10 (BJAB and IARC 518). BJAB may produce hlL-10 as a consequence of an intricate pattern of chromosomic translocations, different from the classical translocations that exist in other Burkitt lymphomas (34) . The mechanisms leading to the production of hlL-10 by the preplasmocytic cell line IARC 518 also remain to be elucidated. This strong association between EBV expression and hlbl0 production by a human B cell line is consistent with the results recently obtained with human B cell lines derived from patients with AIDS and Burkitt lymphoma (35) .
It is important to emphasize that vlL-10 was only seldomly detected and, if so, at low levels. In fact, vlL-10 has been described as being expressed only during the late phase of the virus lyric cycle (36) . Thus, the occasional detection of only low amounts of vlL-10 in the supernatants of lymphoblastoid cell lines is consistent with the fact that EBV is present in these cells in a latent state. It will be of interest to check whether the cell lines producing vlL-10 are also able to produce the virus. Finally, the fact that EBV induces the expression of a cellular gene (hlL-10), with a viral counterpart (vlL-10) already existing within the viral genome, still remains an unresolved issue.
The present study also indicates that the production of hlL-10 by human B cells is not restricted to cell lines since normal B lymphocytes can also secrete hlbl0 after activation. These results are consistent with the detection by PCR of the hlL-10 mRNA for some EBV-transformed B cell lines and also for SAC-activated normal human B lymphocytes (18) . However, whatever the B cell origin (tonsils, spleen, peripheral blood, or cord blood) and the polyclonal activator used, the maximum of hlL-10 production was low (0.35 ng/ml for 106 cells initially seeded). In fact, these levels are comparable to those described for mouse B cells (22) . None of the tested B cell subpopulations (tonsil IgD + or IgD-, cord blood CD5 +) was found to produce higher levels of hlL-10. This is in apparent contrast to results obtained with mouse B cells, where II.-10 production appears to be associated with CD5 expression (32) .
The biological meaning of such a level of Ibl0 secretion remains difficult to establish as concentrations of hlL-10 <0.5 ng/ml do not affect B cell growth or differentiation (19) . Thus, this endogenous production of hlL-10 by B cells does not seem to be sufficient to induce autocrine B cell proliferation or differentiation. This is consistent with the strong B cell progression activity of exogenous IL-10 observed in the CD40 system (19, 20) . In this context, we were particularly surprised by the low hlbl0 levels observed in response to the combination of the CD40 system and SAC, conditions that represent a thymoindependent B cell activation pathway, where large amounts of Igs are secreted (20) . Indeed, we had hypothesized that the important Ig production observed under these culture conditions was the consequence of a high production of endogenous hlL-10. However, an autocrine loop, occurring without release of Ibl0 outside cells, might happen then.
In our hands, EBV was the sole agent able to induce normal human B lymphocytes to secrete high levels of IL-10. Indeed, after EBV transformation of purified normal B cells, a noticeable production of hi1:10 was observed, whereas no vlbl0 induction was detectable. The bib10 secretion was well correlated with the growth of infected cells. The peak of production extended from day 12 to 18, a critical stage for establishment of the cell line. Moreover, two findings indicate that this production of hi1:10 plays a facilitating role in the establishment of the transformed cell line. First, addition of exogenous hi1:10 at the onset of the culture resulted in an earlier and stronger proliferation of the transformed cells. Second, the addition of a blocking polyclonal anti-I1:10 antiserum efficiently slowed down cell growth. However, the neutralizing antiserum did not prevent the transformation of B lymphocytes and the establishment of the cell line. This is consistent with the results obtained with antiviral cytokines as powerful as IFN-c~ or IFN-% which delay but do not prevent the establishment of EBV-transformed cell lines (37, 38) . Taken together, these results suggest that the endogenous hlbl0 secretion is closely associated to the EBV-induced B cell proliferation during the early stages of cell transformation. Once established, the cell line apparently becomes independent of hlbl0 since exogenous bib10 or anti-Ibl0 antibody turn out to be inefficient at this stage. In this context, several cytokines have already been proposed as autocrine growth factors for long-term established human lymphoblastoid cell lines: .I1:5 (39), II:6 (8), adult T cell leukemia--derived factor/thioredoxin (40), TNF-/~ (9), or soluble CD23 (10) . We are presently trying to determine whether hi1:10 plays an autocrine role in the proliferation of Burkitt lymphoma B cell lines and normal B lymphocytes. This may be difficult to establish since the growth of B cells is likely to depend on the coordinated action of several redundant growth factors.
Since secretion of hI1:10 appears in vitro to be related to the proliferation of EBV-infected B lymphocytes, it is tempting to speculate that this cytokine may be involved in vivo in EBV-associated B cell lymphoproliferative disorders. These include infectious mononucleosis and EBV-associated B cell lymphomas of immunocompromised subjects. Studies are presently under way to determine whether patients suffering from such diseases exhibit abnormal levels of hi1:10 within the tumoral area or in their biological fluids. In addition, this endogenous production of hi1:10 by EBV-transformed B lymphocytes may also be involved in an immunosuppressire process in response to the viral infection through two different mechanisms: by inhibiting the production of IFN-% a potent antiviral cytokine (38) produced by T cells and NK ceils (14) , and by inhibiting antigen presentation to T cells (41) . Thus, EBV may induce the secretion of Ibl0 by B lymphocytes to protect itself from the immune reaction subsequent to viral infection. In this context, we recently found that simultaneous addition of EBV and Ibl0 on total PBMC from EBV-positive donors suppresses reactivation of EBVspecific cytotoxicity and permits establishment of lymphoblastoid cell lines (Burdin, N., and F. Rousset, unpublished observations). Taken together, these results suggest that the Ibl0 production by EBV-transformed B cells may also represent an evasion mechanism against the host antiviral systems. Therefore, the EBV-induced production of hlbl0 may play a dual role: (a) by suppressing the antiviral arms of the immune system, and (b) by enhancing the survival and the growth of their hosts, the B lymphocytes.
